Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on ...

Bain Capital will partner with Milacron’s current owner, Hillenbrand, Inc. (NYSE: HI), who will remain a significant investor in the business to accelerate the Company’s continued growth.

Bain Capital now majority owner of Milacron Transaction enhances Hillenbrand's focus on core business Net proceeds to be used to reduce debt BATESVILLE, Ind., March 31, 2025 /PRNewswire ...

With the completion of the sale, Bain Capital now owns approximately 51% of Milacron and has full operational control, while Hillenbrand retains the remaining 49% stake.

Milacron is an injection molding and extrusion business. Photo: Lubos Pavlicek/Zuma Press Hillenbrand has sold a majority stake in Milacron to an affiliate of Bain Capital Special Situations.

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which will retain 20% equity in the new company.

Bain Capital now owns an approximate 51% share and has full operational control of Milacron, while Hillenbrand maintains an ownership stake of approximately 49%. Bain Capital will provide greater ...

Bain Capital now owns an approximate 51% share and has full operational control of Milacron, while Hillenbrand maintains an ownership stake of approximately 49%. Bain Capital will provide greater ...